Loading
A phase 1/2 trial of RO7247669 in melanoma, non-small-cell lung cancer and oesophageal cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04140500 by Hoffmann-La Roche, with 170 participants enrolled, started 2019-11-11 and due to reach its primary completion in 2027-06-30. Interventions recorded: RO7247669.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche) and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Flatiron Health (Roche), Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Flatiron Health (Roche) and the tag pipeline.
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/